Pluri Inc. (PLUR) vs VistaGen Therapeutics, Inc. (VTGN)

Pluri Inc. and VistaGen Therapeutics, Inc. are both Biotechnology companies. Pluri Inc. and VistaGen Therapeutics, Inc. are of similar size ($13.0M and $12.7M). VistaGen Therapeutics, Inc. grew revenue faster over the last twelve months: 287.2% against −24.0%. Pluri Inc. has the higher net margin (−2,344.6% vs −2,703.7%) and the lower return on invested capital (−526.9% vs 0.00%). Across the 17 metrics below, Pluri Inc. leads on 11 and VistaGen Therapeutics, Inc. on 6.

Valuation

Metric PLUR VTGN Biotechnology median
P/E n/m n/m 7.88
P/S 10.07 4.64 11.47
P/B n/m 0.47 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.28 0.74
EV/Sales 30.14 (7.84) 10.73
Earnings yield (233.33%) (614.81%) (28.84%)
Free cash flow yield (197.46%) (538.13%) (23.03%)

Profitability

Metric PLUR VTGN Biotechnology median
Gross margin 44.59% 100.00% 65.16%
Operating margin (2,454.53%) (2,785.69%) 0.00%
Net margin (2,344.59%) (2,703.72%) 0.00%
Free cash flow margin (1,988.48%) (2,490.88%) 0.00%
Return on equity 260.35% (166.46%) (57.72%)
Return on assets (74.95%) (129.22%) (49.22%)
Return on invested capital (526.92%) 0.00% 0.00%

Growth

Metric PLUR VTGN Biotechnology median
Revenue growth (TTM) (23.95%) 287.15% 5.64%
EPS growth (last fiscal year) 31.46% (9.58%) —
Revenue growth, 5-year CAGR 113.32% 3.10% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PLUR VTGN Biotechnology median
Debt to equity (1.62) 0.00 0.00
Current ratio 0.27 3.07 4.73
Net debt to EBITDA (0.83) 0.63 0.96

Dividend

Metric PLUR VTGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric PLUR VTGN Biotechnology median
Market cap 12.96m 12.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack